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Abstract. Glioblastoma multiforme (GBM) is the most 
common and aggressive malignant glioma that is treated with 
first‑line therapy, using surgical resection followed by local 
radiotherapy and concomitant/adjuvant temozolomide (TMZ) 
treatment. GBM is characterised by a high local recurrence 
rate and a low response to therapy. Primitive neuroectodermal 
tumour (PNET) of the brain revealed a low local recurrence 
rate; however, it also exhibited a high risk of cerebrospinal fluid 
(CSF) dissemination. PNET is treated with surgery followed 
by craniospinal irradiation (CSI) and platinum‑based chemo-
therapy in order to prevent CSF dissemination. GBM with 
PNET‑like components (GBM/PNET) is an emerging variant 
of GBM, characterised by a PNET‑like clinical behaviour with 
an increased risk of CSF dissemination; it also may benefit from 
platinum‑based chemotherapy upfront or following failure of 
GBM therapy. The results presented regarding the manage-
ment of GBM/PNET are based on case reports or case series, 
so a standard therapeutic approach for GBM/PNET is not 
defined, constituing a challenging diagnostic and therapeutic 
dilemma. In this report, a case of a recurrent GBM/PNET 
treated with surgical resection and radiochemotherapy as 
Stupp protocol, and successive platinum‑based chemotherapy 
due to the development of leptomeningeal dissemintation and 
an extracranial metastasis, is discussed. A review of the main 
papers regarding this rare GBM variant and its therapeutic 
approach are also reported. In conclusion, GBM/PNET should 
be treated with a multimodal approach including surgery, 
chemoradiotherapy, and/or the early introduction of CSI and 
platinum‑based chemotherapy upfront or at recurrence.
Introduction
Glioblastoma multiforme (GBM; WHO glioma grade IV) 
is the most common primary malignant brain tumour in 
adults characterised by a very poor prognosis with a median 
survival of 15-18 months (1) and less than 5% of patients alive 
at 5 years (2,3). Standard treatment of newly diagnosed GBM 
is maximal safe resection followed by local radiotherapy with 
concomitant and adjuvant temozolomide (TMZ) (4). Despite 
standard therapy, GBM tends to infiltrate brain parenchyma with 
a high local recurrence rate (~90%) and a very low response to 
successive therapy. According to the 2007 WHO guidelines for 
brain tumours (5), the new knowledges on molecular biology 
and cytogenetics have allowed to define emerging GBM vari-
ants (2,6). GBM with primitive neuroectodermal tumour‑like 
components (GBM/PNET) is an emerging variant of GBM, 
which represent nearly 0.5% of GBM cases (6-8). PNET of 
the brain is an aggressive neoplasm which commonly occur in 
children and rarely in adults. Compared to GBM, PNET has a 
similar poor prognosis but has better response to therapy and 
long term survival with a 4‑year survival rate of 38% (9,10). 
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Furthermore this tumour showed a lower rate of local recur-
rence following total resection and a high risk to disseminate 
into the cerebrospinal fluid (CSF). Extracranial metastasis in 
PNET are rare but more frequent than in GBM. PNET is gener-
ally treated with surgery followed by craniospinal irradiation 
(CSI) combined with platinum‑based chemotherapy in order to 
prevent CSF dissemination (11).
In May 2016 the latest WHO Classification of Tumors of 
the Central Nervous System was published. According to this 
new classification the embryonal tumors other than medullo-
blastoma underwent reclassification, with removal of the term 
‘PNET’ from the diagnostic lexicon. The term GBM/PNET 
was then replaced with the term ‘Glioblastoma with primitive 
neuronal component’ (GBM‑PNC).
GBM/PNET tumour presents more in adults and have two 
different histological architectures including the traditional 
astrocytic GBM areas with high expression of GFAP (7) 
and the hypercellular undifferentiated PNET areas, with 
lower expression of GFAP and neuronal immunophenotype 
(S‑100, Synaptophysin, NeuN, NSE and NFP) (7,12,13). 
In magnetic resonance imaging (MRI) the PNET areas of 
hypercellularity are seen as reduced apparent diffusion coef-
ficient (ADC) (14). Regarding genetic alterations it's possible 
to observe ‘glioma‑like’ characteristics, such as 10q deletion, 
EGFR amplification or 1p/19q deletions and ‘PNET‑like’ 
characteristics, such as high Ki‑67 index, N‑myc or C‑myc 
amplifications (7,11). The role of mutations in isocitrate dehy-
drogenase 1 (IDH1) and IDH2 remains controversial. They 
commonly occur in low grade gliomas and secondary GBMs, 
rarely in primary GBMs. IDH1 mutation have been observed 
also in a small percentage of adult PNETs (15-17). The PNET 
components are explained by two main hypotheses (8): 
PNET‑like foci arise from pre‑existing gliomas, most often 
a secondary GBM (neuroblastic or neuronal metaplasia) and 
the clonal expansion of tumour stem cells or progenitor cells 
resulting in PNET‑like nodules (7,15,18).
Since most of the data concerning the management 
of GBM/PNETs are based on single case reports or case 
series (2,7-9,11,12,15,18-20) and despite therapeutic strategies 
have been identified for GMBs and PNETs, a common thera-
peutic protocol for GBM/PNETs has not yet been defined. 
In addition no evidence on treatment survival outcomes are 
published (11). Therefore GBM/PNETs constitute a chal-
lenging diagnostic and therapeutic dilemma, since GBM is 
typically treated with alkylating agents while PNETs respond 
to platinum‑based chemotherapy.
Recent studies showed that GBM/PNETs have a 
PNET‑like clinical behaviour with increased risk of CSF 
dissemination (7,8) and a possible benefit with ‘PNET‑like’ 
platinum‑based chemotherapy upfront or after standard 
therapy for GBM has failed (7,14).
We reported our experience with a recurrent GBM/PNET 
patient, which developed a rare extracranial metastasis, and then 
a review of the main papers reporting this rare GBM variant.
Case report
In February 2016, a 60‑year‑old Caucasian male patient 
referred to our emergency department for ideomotor slowdown 
and occasional speech impairment. Patient was not affected 
by major comorbidities, except for mild emphysema due to 
cigarette smoking.
On admission, neurologic examination evidenced a mild 
right downward drop to the antigravitary Mingazzini test, a flat-
tening of the nasolabial fold and a slight ideomotor slowdown 
with Karnofsky Performance Status (KPS) 100%. No speech 
disorders were detected. Computed tomography (CT) scan of 
the head and contrast‑enhanced MRI of the brain uncovered a 
voluminous left frontal cystic lesion (AP 54 mm x LL 37 mm) 
with compressive effect and perilesional edema. The lesion 
presented heterogeneous post‑contrastografic enhancement of 
the cystic walls and multinodular component anchored to the 
anterosuperior portion of the cyst lesion (Fig. 1). Total body 
(TB) CT scan did not show any extracranial localization.
A paramedian frontal‑parietal craniotomy with gross 
total resection of the neoplasia was performed under local 
anestesia (awake surgery). The lesion, removed en‑bloc, 
presented a central liquid component and extremely vascu-
larized margins (glioma aspects). Postoperative course was 
uneventful. The histopathological examination revealed that 
the tumor tissue was composed of two distinct components. 
An area with severe cellular pleomorphism in a fibrillar back-
ground, typical of malignant gliomas and an area composed 
of markedly hypercellular mass and high nuclear/cytoplasmic 
ratios with small, round, monomorphic and hyperchromatic 
nuclei, typical of neuroendocrine neoplasia (Fig. 2A and B). 
Immunohistochemistry assay showed positivity for glial fibril-
lary acidic protein (GFAP) in the 60% of the cells and for 
Synaptophysin (Syn) in the 40% of the cells (Fig. 2C and D). 
overexpression of EGFR and positivity for P53 protein was 
aslo observed. Ki67 was 70%. Histologic diagnosis, according 
to the current WHO classification (2007) was GBM PNET‑like 
IDH1 wild‑type.
All control brain MRI scans were obteined with 3 
Tesla MRI using gadolinium‑enhanced T1‑weighted, 
T2/FLAIR‑weighted, perfusion‑weighted, diffusion‑weighted 
and MR spectroscopy sequences.
On the 1st postoperative month, at the end of March, the 
patient referred to our emergency department for tonic‑clonic 
seizure with loss of consciousness. A brain MRI was 
performed showing the presence of pathological tissue of 
5x4 cm size involving the corpus callosum. From April to May 
the patient underwent hypofractionated radiotherapy (40 Gy 
in 15 fractions) with concomitant oral TMZ 75 mg/mq/day 
(Stupp protocol).
In May, on the 3rd postoperative month, after the end 
of radio‑chemotherapy, a control brain MRI showed a 
contrast-enhancing centronecrotic nodule in left anterior 
frontal site, adjacent to the previous surgical site, and one in the 
body of the corpus callosum, as for satellite expression of the 
primary tumor. Neurologic examination and KPS were stable. 
The patient started metronomic TMZ 150 mg/day orally for 
5 days every 28 days until the end of the 4th postoperative 
month.
On the 5th postoperative month, after one cycle of TMZ 
150 mg/day, a control brain MRI showed a context of stable 
disease. The patient underwent two additional cycles of oral 
TMZ 300 mg/day for 5 days every 28 days.
In August, on the 6th postoperative month, a control brain 
MRI documented slight volumetric reduction of the two left 
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frontal centronecrotic nodules (10 mm vs. 13 and 5 mm vs. 
10 mm) and of the lesion of the corpus callosum (7 mm vs. 
20 mm) (intracerebral partial response). However it also showed 
contrast‑enhancing leptomeningeal thickening in the left 
temporal lobe (maximum 14 mm), left ethmoido‑sphenoidal 
emiplanum (maximum 12 mm) and left portion of the tento-
rium (maximum 10 mm) (Fig. 3). Moreover, a subcutaneous 
nodule was clinically evident in the left frontal region, at the 
level of the previous craniotomy. Despite the new findings the 
patient was still clinically stable.
In September (7th postoperative month) a surgical exci-
sion of the subcutaneous nodule, under local anesthesia, 
was performed. Histologic examination confirmed a GBM 
PNET‑like extracranial metastasis. Histological and immuno-
histochemical staining showed that the metastasis was almost 
completely composed of the neuroendocrine tumor (95%) 
while the GBM component was limited to 5% of the tumor 
mass (Fig. 4). A TB CT scan of stadiation did not show any 
other extracranial localization, but a further increased of the 
left cerebral leptomeningeal thickening (23 mm vs. 14 mm in 
the temporal lobe).
At the end of September, adjuvant chemotherapy was 
adopted according to the scheme: Carboplatin AUC5 IV day 1 
every 21 days and Etoposide 100 mg/mq IV day 1‑3 every 
21 days. After 2 cycles of chemotherapy, which the patient 
well‑tolerated, a control brain MRI was performed and docu-
mented a significant regression of the diffuse leptomeningeal 
thickening with maximum residual of 4-5 mm (Fig. 5). It also 
showed a stability of left frontomesial nodules and of the 
lesion of the corpus callosum. Patient clinical condition and 
KPS were stable.
On the 9th postoperative month (november) the patient 
underwent 3rd chemotherapy cycle. After several days he 
experienced occasional upper and inferior limb tremors and 
an episode of generalized seizure. Successively he reported 
the onset of weakness and drowsiness followed by aphasia and 
dysphagia.
In December, on the 10th post‑operative month, a brain 
MRI performed shows a massive disease progression with 
increased of leptomeningeal thickening of the left cerebral 
hemisphere, which presents a multinodular contrast‑enhancing 
aspect (Fig. 6). The nodulations have a size between 0.7 and 
2.9 cm and the major nodules are those of the temporal‑insular 
(2.9 cm) and parietal lobe (2.6 and 1.8 cm) with loco‑regional 
parenchymal spread. In the left‑frontal area, at the level of the 
previous craniotomy, a contrast‑enhancing leptomeningeal 
thickening was detected, attributable to local recurrence of the 
Figure 1. Preoperative brain MRI. Preoperative (A) contrast‑enhanced and 
(B) T2‑weighted, coronal and axial MRI cuts showing a large left frontal 
cystic lesion presenting a heterogeneously contrast‑enhanced tissutal compo-
nent and mild perilesional edema. MRI, magnetic resonance imaging.
Figure 2. Interface between the GBM and PNET components in the primitive 
tumor. In the (A) H&E (magnification, x40) and (B) H&E (magnification, 
x100) staining images, on the left there is a typical area of GBM with severe 
cellular pleomorphism in a fibrillar background and on the right there is an 
area of PNET composed of a high cellular mass with small, round, mono-
morphic and hyperchromatic nuclei. (C) Syn staining (magnification, x40) 
revealed a PNET component, while (D) the glial fibrillary acidic protein 
immunohistochemical staining (magnification, x40) defined the GBM coun-
terpart. GBM, glioblastoma multiforme; PNET, primitive neuroectodermal 
tumour; H&E, hematoxylin and eosin.
Figure 3. Contrast‑enhanced brain magnetic resonance imaging at postopera-
tive month 6, following adjuvant temozolomide. A paracentimetric frontal 
centronecrotic nodule with peripheral enhancement is evident anteriorly 
to the previous surgical bed. Left fronto‑temporal and fronto‑basal diffuse 
leptomeningeal neoplastic ‘en plaque’ seeding are also present.
Figure 4. Histology of the subcutaneous metastasis. (A) Hematoxylin and 
eosin (magnification, x40), and (B) Syn staining (magnification, x40) demon-
strated that the metastasis is almost entirely composed of the neuroendocrine 
tumor (95%). The glioblastoma multiforme component is limited to 5% of the 
tumor. There is no evidence of necrotic areas.
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disease. At the end of the 10th postoperative month the patient 
died for the evolution of the disease. Informed consent was 
obtained from the parents of the subject for participation in 
the present study.
Discussion
GBM and PNETs of the brain showed different pattern of 
recurrence and this is reflected in the different standard of 
treatment. GBM has a local infield pattern of recurrence so 
the standard therapy consists of surgery followed by chemo-
radiotherapy in order to improve local control. For recurrent 
GBM different therapeutic approaches are provided such as 
resurgery, reirradiation and systemic chemotherapy based 
on alkylating agents, bevacizumab, carboplatin, etoposide 
and their combination (21). On the other hand PNETs of the 
brain show a high tendency of leptomeningeal dissemination 
and extracranial metastasization (22), so the standard therapy 
consists of surgery followed by CSI combined with concurrent 
platinum‑based chemotherapy, particularly carboplatin, or 
other concomitant chemotherapeutic agents, such as etoposide 
and TMZ (11).
Some genetic alterations are expressed more frequently in 
secondary GBMs including O6‑methylguanine‑DNA methyl-
transferase (MGMT) promoter methylation (36% of primary 
vs. 75% of secondary GBMs) and IDH1 and IDH2 mutations 
(70‑80% of low grade gliomas and secondary GBMs), which 
correlate to an improved prognosis (15).
MGMT promotor methylation is associated with better 
response rate, progression‑free survival (PFS) and overall 
survival (OS) in GBMs treated with radiotherapy and/or chemo-
therapy with alkylation agents (TMZ) in newly diagnosed and 
recurrent GBMs (23).
Also IDH1/IDH2 mutations are correlated with better OS 
and PFS. In addition, IDH1 mutated GBM patients undergone 
complete resection have an improved survival. IDH1 muta-
tions have been observed in a small percentage of adult PNETs 
and of GBM/PNETs and seem to have a positive prognostic 
value (15). The possibility that the emergence of PNET‑like 
elements may preferentially occur in secondary GBMs with 
wild‑type IDH genes should be evaluated (20). EGFR muta-
tion/amplification correlates with better prognosis when 
associated with methylated MGMT promotor (23).
In contrast to GBMs and PNETs, there is no standard 
treatment for GBM/PNETs because the majority of the avail-
able data on their therapeutic approach derived from case 
reports and case series (Table I).
The largest series published on GBM/PNETs belong to 
Varlet et al (n=40) (19) and Perry et al (n=53) (7), which showed 
the clinical, radiological and histopathological differences 
of this variant of GBM compared to classic GBM and used 
for the first time the term ‘malignant glioma with PNET‑like 
component (MG‑PNET)’.
In 2004 Varlet et al (19) reported that local radiotherapy 
was an inadequate method for preventing the tumour spreading 
and mentioned chemotherapy as a more efficient therapeutic 
approach.
The largest multi‑institutional case series was performed 
by Perry et al (7) in 2009 which studied 53 GBM/PNET 
patients treated with radiation (78%), TMZ (63%) and plat-
inum‑based chemotherapy (31%). Nineteen patients underwent 
surgical resection with 18 patients (78%) received adjuvant 
radiotherapy (17 local and one cranio‑spinal), of which 14 
were treated with concomitant chemotherapy (OS from 
1 month to 3.3 years, median OS‑mOS=12 months). Sixteen 
patients (70%) received adjuvant GBM‑like chemotherapy, 
including TMZ and BCNU (OS from 1 month to 3.3 years, 
mOS=8 months). Three patients received ‘PNET‑like’ 
platinum‑based chemotherapy upfront with survival of 10 
and 20 months in two patients. In 3 patients, therapy was 
switched from TMZ to platinum‑based regimens after signs 
of progression on imaging, with radiological responses (1). 
The mOS of all patients was 9.1 months, a survival similar to 
that reported for MGs. Perry et al (7) reported also a higher 
frequency of IDH mutations in GBM/PNETs compared 
to primary GBMs (7%), supporting the hypothesis of a 
secondary GBM origin for most of GBM/PNET cases. They 
concluded that the addition of platinum‑based chemotherapy 
should be considered in order to prevent CSF dissemination, 
particularly after failure with TMZ, and appeared to improve 
survival.
Also Song et al (15) in 2011 observed a high frequency (25%) 
of IDH1 mutations in the cases analysed for this mutations. 
Moreover, the IDH1 mutated patients were still alive 14 and 
31 months after diagnosis, underlying the correlation between 
IDH1 mutations and improved prognosis.
Figure 5. Contrast‑enhanced brain MRI at postoperative month 9. Following 
2 cycles of carboplatin and etoposide chemotherapy, brain MRI revealed 
stability of the left frontal paracentimetric nodule and a marked reduction of 
the frontotemporal leptomeningeal ‘en plaque’ localization. MRI, magnetic 
resonance imaging.
Figure 6. Contrast‑enhanced brain MRI at postoperative month 10. Following 
3 cycles of carboplatin and etoposide chemotherapy, brain MRI revealed that 
the left frontal paracentimetric centronecrotic nodule was no longer evident. 
Recurrence of the frontotemporal and frontobasal ‘en plaque’ localization as 
well as the evidence of two novel left parietal localizations were presented 
with a dural implant. MRI, magnetic resonance imaging.
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In 2012 Karina et al (20) described a case of a GBM/PNET 
patient which underwent surgery and chemoradiotherapy as 
Stupp protocol. Platinum‑based chemotherapy was reserved 
for recurrence or failure.
In the same year Lee et al (24) analysed 3 GBM/PNET cases 
treated with surgery followed by adjuvant radio‑chemotherapy 
including TMZ and carboplatin. After 4 week break, 3 cycles 
of consolidation chemotherapy with ifosfamide, carboplatin 
and etoposide were performed followed by adjuvant TMZ. 
Overall this protocol appears to improve survival compared 
to the literature.
In 2015 Kimbason et al (18) reported a case series of 
5 GBM/PNET patients treated with surgical resection 
followed by chemoradiotherapy with TMZ and then different 
chemotherapy regimens. Two patients received platinum‑based 
therapy with carboplatin and showed longer survival since 
diagnosis. The authors supported that GBM/PNET patients 
should be treated aggressively using a multimodal approach 
including maximal surgical resection, radiation therapy and 
platinum‑based chemotherapy to better address the PNET 
component.
Chu et al (8) in 2015 described a case of a recurrent 
GBM/PNET patient treated with multiple courses of surgery, 
radiation and chemotherapy regimens including TMZ, 
procarbazine with lomustine and vincristine (PCV), bevaci-
zumab, carboplatin and etoposide. This approach resulted in 
modest local responses and control. This case suggested that 
aggressive therapies, with the early introduction of CSI and 
platinum‑based chemotherapy may be utilized in attempts to 
have a better disease control and a longer survival.
Recently Forbes and Vredenburgh (9) reported a case of 
GBM/PNET composed of predominately PNET with small areas 
of GBM positive for GFAP (10%) treated with surgical resec-
tion, radiotherapy and chemotherapy targeting both the PNET 
and GBM components. The patient underwent CSI followed 
by 12 cycles of alternating chemotherapy based on cisplatin, 
vincristine, cyclophosphamide to target the PNET component 
and TMZ with etoposide to target the GBM component. With 
this multimodal approach and combination of chemotherapeutic 
agents the patient did not show any sign of recurrence.
In 2016 O'Leary et al (11) have raised the doubt that using 
a CSI irradiation with concomitant PNET‑like chemotherapy 
could under‑treat the GMB component of GBM/PNET, espe-
cially in those with MGMT methylation. In their study, they 
showed that CSI associated with TMZ could represent a good 
choice for patients with TMZ‑sensitive tumours with high risk 
of CSF spread.
In 2017 Konar et al (22) reported a case of GBM/PNET which 
developed extraparenchymal metastasis (dural metastasis) 
of pure PNET component after surgery and chemoradio-
therapy as Stupp protocol. According to the authors early 
CSI in GBM/PNET patients should be performed, even after 
completion of adjuvant radio‑chemotherapy.
GBM/PNET represents a diagnostic and therapeutic chal-
lenge since the two histological components have distinct 
clinico‑pathological characteristics, treatment features and 
prognosis (20). In GBM/PNETs the role of surgery and 
radiotherapy as a first phase approach is established. The 
fulcrum of the therapeutic dilemma is represented by the 
choice of the best chemotherapy which should target both 
GBM and PNET components and should be driven by the their 
histological predominance.
In a clinical context, the therapeutic rationale for 
GBM/PNET is trying to combine the gold‑standard treatment 
for the GBM component with an adequate therapeutic coverage 
for the risk of CSF dissemination, typical of PNETs. A possible 
therapeutic strategy could be represented by surgical resection 
followed by radiotherapy, suitable for either the GBM and 
PNET components, combining alkylating agents. According to 
the predominance of GBM or PNET component, radiotherapy 
could consist of focal irradiation, as Stupp protocol, or CSI with 
concomitant and adjuvant TMZ, respectively (4,11). An early 
introduction of ‘PNET‑like’ platinum‑based chemotherapy 
should be planned in order to prevent CSF dissemination or in 
case of disease recurrence (7,8,14,18,20).
Therefore it's fundamental to assess the two components 
of GBM/PNET in order to guarantee the best treatment 
choice (20). The preoperative identification of areas of reduced 
ADC, typically of PNET‑foci, on MRI should address to 
consider the diagnosis of GBM/PNET and to make targeted 
biopsies (14,15). Regarding the immunohistochemical findings, 
the two components of GBM/PNET should be identified with 
the use of GFAP and neuronal markers in order to quantify the 
two histologies and plan successive therapeutic approaches.
Further studies on different treatment approaches with 
long‑term follow up are needed to optimize treatment algo-
rithm of this rare tumour type. Moreover new molecular targets 
related to novel targeted therapies and newer biomarkers 
related to clinical outcome are currently under investigation 
for gliomas and PNETs. Many advances in the understanding 
of cancer biology are made in the field of gene sequencing 
and interaction with tumor microenvironment. They aim to 
identify alterations of the immune system defing immune 
phenotypes (25,26) and cancer pathways associated with 
intracellular and intercellular signaling important to mediate 
cancer pathogenesis and progression (27-33).
In conclusion our case report and the review of the 
literature support the view that GBM/PNET should be treated 
aggressively using a multimodal approach including surgery, 
chemoradiotherapy and/or the early introduction of CSI and 
platinum‑based chemotherapy upfront or at recurrence, in 
order to target both the PNET and GBM components.
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